Switch theme
Sign up to access all valuation multiples
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.
n/a
LTM Revenue $254M
LTM EBITDA -$60.0M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SK Bioscience has a last 12-month revenue of $254M and a last 12-month EBITDA of -$60.0M.
In the most recent fiscal year, SK Bioscience achieved revenue of $182M and an EBITDA of -$24.7M.
SK Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SK Bioscience valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $252M | $182M | XXX | XXX | XXX |
| Gross Profit | $163M | $96.9M | XXX | XXX | XXX |
| Gross Margin | 65% | 53% | XXX | XXX | XXX |
| EBITDA | $29.6M | -$24.7M | XXX | XXX | XXX |
| EBITDA Margin | 12% | -14% | XXX | XXX | XXX |
| Net Profit | $83.4M | $15.2M | XXX | XXX | XXX |
| Net Margin | 33% | 8% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, SK Bioscience's stock price is KRW 39300 (or $27).
SK Bioscience has current market cap of KRW 3.02T (or $2.1B), and EV of KRW 2.25T (or $1.5B).
See SK Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $2.1B | XXX | XXX | XXX | XXX | $-0.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, SK Bioscience has market cap of $2.1B and EV of $1.5B.
SK Bioscience's trades at 6.1x LTM EV/Revenue multiple, and -25.6x LTM EBITDA.
Analysts estimate SK Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for SK Bioscience and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 8.4x | XXX | XXX | XXX |
| EV/EBITDA | -62.3x | XXX | XXX | XXX |
| P/E | -56.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -7.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSK Bioscience's NTM/LTM revenue growth is 76%
SK Bioscience's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, SK Bioscience's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate SK Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for SK Bioscience and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -28% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -14% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -183% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 63% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 27% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 63% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SK Bioscience acquired XXX companies to date.
Last acquisition by SK Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . SK Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| Where is SK Bioscience headquartered? | SK Bioscience is headquartered in South Korea. |
| Who is the CEO of SK Bioscience? | SK Bioscience's CEO is Mr. Jae-yong Ahn. |
| Is SK Bioscience publicy listed? | Yes, SK Bioscience is a public company listed on KRX. |
| What is the stock symbol of SK Bioscience? | SK Bioscience trades under 302440 ticker. |
| When did SK Bioscience go public? | SK Bioscience went public in 2021. |
| Who are competitors of SK Bioscience? | Similar companies to SK Bioscience include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of SK Bioscience? | SK Bioscience's current market cap is $2.1B |
| What is the current revenue of SK Bioscience? | SK Bioscience's last 12-month revenue is $254M. |
| What is the current EBITDA of SK Bioscience? | SK Bioscience's last 12-month EBITDA is -$60.0M. |
| What is the current EV/Revenue multiple of SK Bioscience? | Current revenue multiple of SK Bioscience is 6.1x. |
| What is the current EV/EBITDA multiple of SK Bioscience? | Current EBITDA multiple of SK Bioscience is -25.6x. |
| What is the current revenue growth of SK Bioscience? | SK Bioscience revenue growth between 2023 and 2024 was -28%. |
| Is SK Bioscience profitable? | Yes, SK Bioscience is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
